(Ezekiel Loseke, Headline USA) A new, more traditional variety of vaccine has received emergency approval from the Food and Drug Administration.
Politico reported that the new vaccine is a two-dose treatment that must be administered three weeks apart. The vaccine was made with insect protein and bark from a tree in Chile, making it more traditional than previous jab juice used in messenger RNA vaccines and Johnson & Johnson’s shot.
The shot is intended to be used by the population that has not already received one of the three earlier vaccines, about 10% of the American people, according to Politico.
FDA Commissioner Robert Calif said, “Today’s authorization offers adults in the United States who have not yet received a COVID-19 vaccine another option that meets the FDA’s rigorous standards for safety, effectiveness, and manufacturing quality needed to support emergency use authorization.”
The shot, like older vaccines, is intended to create an immune system response that prepares the body to fight off the COVID-19 virus. The new shot is reportedly 90% effective.
The Centers for Disease Control and Prevention has not yet endorsed the use of the new vaccine for adults, but is scheduled to hold a meeting on July 19 that will address that possibility.
The Biden administration is bullish on the new vaccine. According to Politico, officials said it is “expected to complete all necessary quality testing in the next few weeks, which would support final release of the product.”
If the vaccine, which had the Trump administration’s strong backing, gets CDC approval, it will be provided to “states, jurisdictions, federal pharmacy partners, and federally qualified health centers,” per Politico.
